This is a preview of subscription content, access via your institution.
References
Wilkes MS, Bell RA, Kravitz RL. Direct-to-consumer prescription drug advertising: trends, impact, and implications. Health Aff. 2000; 19: 110-128.
Huh J, DeLorme DE, Reid LN, An S. Direct-to-consumer prescription drug advertising: History, regulation, and issues. Minn Med. 2010; 93: 50-52.
Mackey TK, Yagi N, Liang BA. Prescription drug coupons: Evolution and need for regulation in direct-to-consumer advertising. Research in Social & Administrative Pharmacy: RSAP. 2013. doi:10.1016/j.sapharm.2013.08.002.
Perri M 3rd, Shinde S, Banavali R. The past, present, and future of direct-to-consumer prescription drug advertising. Clin Ther. 1999; 21: 1798-1811. discussion 1797.
Talley CR. Direct-to-consumer prescription drug advertising. Am J Health-Syst Pharm: AJHP: Off J Am Soc Health-Syst Pharm. 1997; 54: 2181.
Vitry AI. Does direct-to-consumer prescription drug advertising do more harm than good? Ann Intern Med. 2009; 151: 823-824. author reply 824.
Schwartz LM, Woloshin S. Communicating uncertainties about prescription drugs to the public: A national randomized trial. Arch Intern Med. 2011; 171: 1463-1468.
Schwartz LM, Woloshin S. The Drug Facts Box: Improving the communication of prescription drug information. Proc Natl Acad Sci U S A. 2013; 110(Suppl 3): 14069-14074.
Schwartz LM, Woloshin S, Welch HG. The drug facts box: Providing consumers with simple tabular data on drug benefit and harm. Med Decis Making: An Int J Soc Med Decis Mak. 2007; 27: 655-662.
Schwartz LM, Woloshin S, Welch HG. Using a drug facts box to communicate drug benefits and harms: Two randomized trials. Ann Intern Med. 2009; 150: 516-527.
Woloshin S, Schwartz LM. The new weight-loss drugs, Lorcaserin and Phentermine-Topiramate: Slim pickings? JAMA Internal Medicine. 2014. doi:10.1001/jamainternmed.2013.14629.
Woloshin S, Schwartz LM, Welch HG. The value of benefit data in direct-to-consumer drug ads. Health affairs Suppl Web Exclusives. 2004; W4: 234-245.
O'Donoghue AC, Sullivan HW, Aikin KJ. Randomized study of placebo and framing information in direct-to-consumer print advertisements for prescription drugs. Ann Behav Med. 2014. doi:10.1007/s12160-01409603-1.
Author’s Statement of Conflict of Interest
Lila J. Finney Rutten declares that she has no conflict of interest.
Author information
Authors and Affiliations
Corresponding author
About this article
Cite this article
Rutten, L.J.F. Leveraging Health Communication Research to Inform Regulation of Direct-to-Consumer Ads for Prescription Medications: a Comment on O’Donoghue et al.. ann. behav. med. 48, 291–292 (2014). https://doi.org/10.1007/s12160-014-9611-1
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12160-014-9611-1
Keywords
- Placebo
- Prescription Medication
- Patient Engagement
- Communication Factor
- Accurate Perception